ABIVAX Société Anonyme (ABVX) Expected to Announce Earnings on Monday

ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Monday, June 2nd. Analysts expect the company to announce earnings of ($1.59) per share and revenue of $3.11 million for the quarter.

ABIVAX Société Anonyme Stock Performance

Shares of ABVX traded up $0.02 during trading hours on Friday, reaching $6.04. 7,279 shares of the company's stock traded hands, compared to its average volume of 141,677. ABIVAX Société Anonyme has a 12 month low of $4.77 and a 12 month high of $14.71. The firm's 50 day simple moving average is $6.25 and its 200-day simple moving average is $6.98.

Hedge Funds Weigh In On ABIVAX Société Anonyme

Large investors have recently modified their holdings of the company. Woodline Partners LP grew its position in ABIVAX Société Anonyme by 319.5% during the first quarter. Woodline Partners LP now owns 201,924 shares of the company's stock valued at $1,262,000 after acquiring an additional 153,788 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of ABIVAX Société Anonyme by 6.0% in the 1st quarter. Millennium Management LLC now owns 987,414 shares of the company's stock worth $6,171,000 after acquiring an additional 56,235 shares during the last quarter. Cubist Systematic Strategies LLC boosted its stake in shares of ABIVAX Société Anonyme by 34.3% in the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company's stock valued at $63,000 after purchasing an additional 2,595 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of ABIVAX Société Anonyme by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock valued at $41,000 after purchasing an additional 1,990 shares during the last quarter. 47.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ABVX. Morgan Stanley reiterated an "equal weight" rating and set a $12.00 target price on shares of ABIVAX Société Anonyme in a research report on Thursday, March 20th. JMP Securities reaffirmed a "market outperform" rating and set a $33.00 price objective on shares of ABIVAX Société Anonyme in a report on Wednesday, April 30th.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.